User login
New results from the Neo ALTTO, I-SPY 2, and IBIS-II trials will head up our onsite coverage of the San Antonio Breast Cancer Symposium, to be held Dec. 10-14.
Survival follow-up analysis of the Neo ALTTO study (BIG 1-06)
Reports on new therapies in the neoadjuvant setting at SABCS will include the latest survival follow-up analysis from the Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study. The results examine the association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.
To put the new findings in perspective, read our prior report on Neo ALTTO as well as a study that examined the effect of Neo ALTTO findings on treatment decisions.
Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer
First results from the I-SPY 2 trial will examine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response over standard neoadjuvant chemotherapy for specific biomarker signatures established at trial entry.
Anastrozole as preventive therapy in postmenopausal women at increased risk of breast cancer
First results of the IBIS-II (International Breast Cancer Intervention Study II) trial will examine the outcomes of women who were at high risk for breast cancer and given either anastrozole or placebo. Guidelines on preventive therapy, issued earlier this year by the U.S. Preventive Services Task Force, did not include recommendations regarding the aromatase inhibitor anastrozole, pending the data from the IBIS-II trial.
Look for your newsletters featuring these reports and our insightful video interviews with researchers who put the findings into perspective for your practice. Our next-best-thing-to-being-there coverage of SABCS begins on Dec. 10.
New results from the Neo ALTTO, I-SPY 2, and IBIS-II trials will head up our onsite coverage of the San Antonio Breast Cancer Symposium, to be held Dec. 10-14.
Survival follow-up analysis of the Neo ALTTO study (BIG 1-06)
Reports on new therapies in the neoadjuvant setting at SABCS will include the latest survival follow-up analysis from the Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study. The results examine the association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.
To put the new findings in perspective, read our prior report on Neo ALTTO as well as a study that examined the effect of Neo ALTTO findings on treatment decisions.
Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer
First results from the I-SPY 2 trial will examine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response over standard neoadjuvant chemotherapy for specific biomarker signatures established at trial entry.
Anastrozole as preventive therapy in postmenopausal women at increased risk of breast cancer
First results of the IBIS-II (International Breast Cancer Intervention Study II) trial will examine the outcomes of women who were at high risk for breast cancer and given either anastrozole or placebo. Guidelines on preventive therapy, issued earlier this year by the U.S. Preventive Services Task Force, did not include recommendations regarding the aromatase inhibitor anastrozole, pending the data from the IBIS-II trial.
Look for your newsletters featuring these reports and our insightful video interviews with researchers who put the findings into perspective for your practice. Our next-best-thing-to-being-there coverage of SABCS begins on Dec. 10.
New results from the Neo ALTTO, I-SPY 2, and IBIS-II trials will head up our onsite coverage of the San Antonio Breast Cancer Symposium, to be held Dec. 10-14.
Survival follow-up analysis of the Neo ALTTO study (BIG 1-06)
Reports on new therapies in the neoadjuvant setting at SABCS will include the latest survival follow-up analysis from the Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study. The results examine the association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.
To put the new findings in perspective, read our prior report on Neo ALTTO as well as a study that examined the effect of Neo ALTTO findings on treatment decisions.
Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer
First results from the I-SPY 2 trial will examine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response over standard neoadjuvant chemotherapy for specific biomarker signatures established at trial entry.
Anastrozole as preventive therapy in postmenopausal women at increased risk of breast cancer
First results of the IBIS-II (International Breast Cancer Intervention Study II) trial will examine the outcomes of women who were at high risk for breast cancer and given either anastrozole or placebo. Guidelines on preventive therapy, issued earlier this year by the U.S. Preventive Services Task Force, did not include recommendations regarding the aromatase inhibitor anastrozole, pending the data from the IBIS-II trial.
Look for your newsletters featuring these reports and our insightful video interviews with researchers who put the findings into perspective for your practice. Our next-best-thing-to-being-there coverage of SABCS begins on Dec. 10.